These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20510041)

  • 21. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
    Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
    Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
    Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
    Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease.
    Keegan A; Charest K; Schmidt R; Briggs D; Deangelo DJ; Li B; Morgan EA; Pozdnyakova O
    J Clin Pathol; 2018 Jul; 71(7):653-658. PubMed ID: 29588374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical significance of sequential monitoring minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
    Wang L; Jiang H; Li H; Shao JB; Lu ZH; Yang JW; Yang WQ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):400-3. PubMed ID: 21781499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
    Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical value of minimal residual disease detection by flow cytometry in childhood B-cell acute lymphoblastic leukemia].
    Chang L; Zhang G; Shi H; Ye L; Jiang YM
    Zhongguo Dang Dai Er Ke Za Zhi; 2014 Dec; 16(12):1245-9. PubMed ID: 25523574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of the immunophenotype of patients with B lineage acute lymphoblastic leukemia at diagnosis and relapse].
    Liu YR; Chang Y; Fu JY; Cheng YF; Zhang LP; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):335-8. PubMed ID: 16875586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
    Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.
    Keeney M; Halley JG; Rhoads DD; Ansari MQ; Kussick SJ; Karlon WJ; Mehta KU; Dorfman DM; Linden MA
    Arch Pathol Lab Med; 2015 Oct; 139(10):1276-80. PubMed ID: 25695342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD317 is over-expressed in B-cell chronic lymphocytic leukemia, but not B-cell acute lymphoblastic leukemia.
    Gong S; Osei ES; Kaplan D; Chen YH; Meyerson H
    Int J Clin Exp Pathol; 2015; 8(2):1613-21. PubMed ID: 25973046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.
    Borowitz MJ; Pullen DJ; Shuster JJ; Viswanatha D; Montgomery K; Willman CL; Camitta B;
    Leukemia; 2003 Aug; 17(8):1566-72. PubMed ID: 12886244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
    Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ
    Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia].
    Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.